Trials / Completed
CompletedNCT00170833
Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients
A Prospective, Multicenter, Open Label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus (RAD001) With Basiliximab, Corticosteroids and Lower Levels Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Recipients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
This study will assess the safety and efficacy of everolimus with basiliximab, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2005-11-01
- First posted
- 2005-09-15
- Last updated
- 2011-11-02
Source: ClinicalTrials.gov record NCT00170833. Inclusion in this directory is not an endorsement.